WWW.IJRPR.COM

**International Journal of Research Publication and Reviews**

Journal homepage: www.ijrpr.com ISSN 2582-7421

# Optimization of Colon-Specific Microspheres for Enhanced 5-Fluorouracil Delivery

*[1]Arti Deshmukh, [2]Aditya Tiwari, [3]NK Sahu*

**[1]Research Scholar, Millennium College of Pharmacy, Bhopal, Madhya Pradesh- 462026, India**
**[2] Associate Professor, Millennium College of Pharmacy, Bhopal, Madhya Pradesh- 462026, India**
**[3] Principal, Millennium College of Pharmacy, Bhopal, Madhya Pradesh- 462026, India**

**ABSTRACT:**

The colon is a site where both neighborhood and foundational conveyance of medications can take place. Local conveyance might permit skin therapy of colorectal disease. Treatment might be made more powerful if drug(s) can be focused on straight forwardly to the colon prompting decrease in foundational aftereffects. Traditional medication conveyance framework for therapy of colorectal malignant growth are bombing as the medication doesn't arrive at the site of activity in proper focus, because of unfriendly climate of upper GIT, and retention of most extreme controlled portion from upper GIT which produce serious harmful outcome. In the current review it willpropose to plan eudragit S-100 covered starch microspheres typifying the anticancer medication (5-fluorouracil). Normal polysaccharides starch is picked for arrangement of microspheres on the grounds that they are easilydegraded bythe microbial vegetation/compounds present in the colon. These microspheres will additionally be covered with pH touchy polymers (which breaks down at or above pH 6.4). By utilizing pH sensitivepolymers the microspheres will stay in salvageable shape all through the GI plot and delivery the medication explicitly close to the colon district. Hence readiness of colon explicit microspheres of 5-fluorouracil will improvethe restorative adequacy of the medication by nearby activity and lessen aftereffects by limiting the fundamental retention of drug.The significant target of the current work is to plan, advanced and described eudragit S-100 covered starch microspheres typifying the 5-fluorouracil for site explicit colon drug conveyance. The starch microspheres of 5-FU drug were ready by changed emulsion cross-connecting technique. Themicrospheres wereprepared byusingtwo various stages thencoatedwith eudragit S-100. The arranged microspheres were assessed for boundaries, for example, molecule size, the shape and surface qualities of the microspheres, stream properties, rate yield, drug stacking limit and level of enlarging of various clusters and the outcome was presumed that these were relying upon the higher level of starch polymer duringthe plan. Colon designated microspheres FCT6 was found best definitions containing normally happening polysaccharide polymeric mix as for example starch with 10 % eudragit S100 covering that discharge more than 99 % of the medication in gastric climate in controlled and supported way upto 12 h.

## 1. Introduction:

Disease of colon and rectum is quite possibly of the most well-known inside danger. Colorectal malignant growth is the subsequent driving reason for disease passings in the US. In 2006 around 1,45,290 new instances of colon cancerwere analyzed in theUnitedStates. Majorityofpeoplesuffering from colorectal malignant growth are beyond 50 years old. Dietary factors, for example, low folate admission are remembered to build the gamble of colorectal malignant growth by 2 to multiple times (1). The occurrence of colorectal disease in any case, could be diminished dramaticallyby preventive techniques like colonoscopy and location of changes in waste DNA (2). Practically all instances of colorectal disease start with the improvement of harmless or noncancerous polyps. At the point colon cancercells spread outsidethecolon orrectum to lymph hubs, it mayalso spread to otherlymph hubs, the liver, or different organs (3, 4). Chemotherapy is utilized to treat progressed colorectal disease. Nonetheless, customary chemotherapy isn't as powerful in that frame of mind for what it's worth in different diseases, as the medication focuses(5,6).The accompanying chemotherapeutic medication sare used alone orin combination to treat colorectal cancer Fluorouracil(5-FU)often used in blend with leucovorin for a very long time after a medical procedure. Fiery inside disorder (ulcerative colitis, Crohn's sickness and so forth), irresistible infections (for example amoebiasis) and colon malignant growth are falling flat, as the medication don't arrive at the site of activity at suitable focuses. For protected and viable treatment, definitions that delivery drug into colon rather thanupper digestive system are useful. This can be achieved by safe explicit medication conveyance to colon. Neighborhood conveyance might permit skin therapy of colorectal disease. Therapy perhaps made more powerful if drug(s) can be focused on straightforwardly to the colon prompting decrease in foundational side effects.Conventional drug conveyance framework for therapy of colorectal disease are bombing as the medication doesn't arrive at the site of activity in suitable fixation, because of threatening climate of upper GIT, and retention of greatest controlled portion from upper GIT which produce serious harmful result. Site-explicit oral medication conveyance requires definite situation of a medication deliverydevice at an ideal site inside the gastro digestive system. In spite of the fact that it is essentially conceivable to confine a gadget inside each piece of gastro digestive system, the fulfillment of site-explicit conveyance in the oral depression and the rectum is somewhat simpler than in the stomach and the little and digestive organs. The last option requires thought of both longitudinal and cross over parts of gastro digestive system limitations [7, 8]. A designated drug deliverysystem is favored these circumstances like Drug (drug flimsiness, low dissolvability) Pharmacokinetic (short half life, enormous volume of

conveyance, unfortunate retention) Pharmacodynamics (low particularity, low restorative file) [9, 10In the current review it will propose to plan eudragit S-100 covered starch microspheres typifying the anticancer medication (5-fluorouracil). Regular polysaccharides starch is picked for development of microspheres on the grounds that they are effectively corrupted by the microbial greenery/compounds present in the colon. These microspheres will additionally be covered with pH delicate polymers (which disintegrates at or above pH 6.4). By utilizing pH touchy polymers the microspheres will stay in salvageable shape all through the GI parcel and delivery the medication explicitly close to the colon locale.

## 2. MATERIAL AND METHODS

Material: The drug 5-fluorouracil (5- FU) was provided as a free sample by Biochem Pharmaceutical IndustriesLtd-Daman. Starch was obtained from Himedia Laboratories Pvt. Ltd. in Mumbai, and Eudragit S-100 from Rhom (GmBH, Germany).Petrolium ether, light liquid paraffin, glutaraldehyde, span 80, and n hexane were obtained from Central Drug House Pvt. Ltd. in Mumbai, and all chemicals were of analytical grade.Methods:

**Determination of absorption maxima:** The absorption maxima (max) of drug were determined by scanning the drug solution in 0.1 N Hcl, pH 7.4, pH 6.8 phosphate buffer, and 4% rat caecal medium. The spectrum of these solutions was measured in a double beam UV spectrophotometer (Shimadzu, UV-1800, A11454500755/UV-1800, Shimadzu Corporation, Kyoto, Japan) in the 200-400 nm range. Figures 1 to 4 show the spectrums




**Figure1:UV absorption maxima of drug in simulated gastric fluid(pH1.2) atλmax 262.0nm**




**Figure2: UV absorption maxima of drug in Phosphate Buffer Solution (pH 7.4) at λ max 266.0 nm**




**Figure 3: UV absorption maxima of drug in simulated intestinal fluid (pH 6.8) at λ max 266.0 nm**




**Figure 4: UV absorption maxima of 5-FU in simulated colonic fluid containing 4% w/v of rat caecal content at λ max 267.0 nm**

**Preparation of Standard Curve of Drug Sample:** The standard curve of 5FU drug was measured in simulatedgastricfluidofpH1.2atλmax 262.0nm,pH7.4atλmax266.0,pH6.8atλmax 266.0nmand simulated colonic fluid containing 4% w/v of rat caecal content at λmax 267.0 nm against a reagent blank (Figure)




**Figure5:Standard curve of 5-FU ins imulated gastric fluid (pH 1.2) at 262.0**




**Figure6:Standard curve of 5-FU in phosphate buffers olution (pH7.4) at 266.0**




**Fig7:Standard curve of 5-FU in simulated intestinal fluid (pH-6.8) at 266.0nm**




**Figure 8: Standard curve of 5-FU in simulated colonic fluid containing 4% w/v of rat caecal content at λ max 267.0 nmInfrared Spectroscopy of 5-FU: :**

It was done by making pellets of the drug in KBr. The observed peaks were compared with those reported for functional groups (Table 1, Figure 9 - 10). There was no interference in functional group of drug 5FU due to presence of all excipients (Table2)




**Figure9:Standard IR spectra of 5-fluorouracil**



**Figure10:IR spectra of 5-fluorouracil (Sample)**

**Table1:Important band frequencies in IR spectrum of 5-FU**

| S. No. | Named Group | Reported Band frequency | Band frequency obtained |
|---|---|---|---|
| 1. | NHstretch | 3127 | 3112.0 |
| 2. | C=Ostretch | 1716and 1657 | 1730.0 & 1661.6 |
| 3. | CH in plane deformation | 1265 | 1246.5 |
| 4. | CH out ofplanedeformation | 812 | 818.4 |
| 5. | C-F | 1058 | 998.3 |
| 6. | Benzenering | 1435 | 1502.0 |

**Table2:Absorbance data for interference of additives in the estimation of 5-FU**

| S. No. | Additives | Absorbanceof 5-FU | Remarks |
|---|---|---|---|
| 1. | Control | 0.6027 | - |
| 2. | Starch | 0.6003 | No change |
| 3. | EudragitS100 | 0.6036 | No change |

**Preparation of Starch Microspheres:** The starch microspheres of 5-FU drug were ready by adjusted emulsion cross-connecting strategy. The microspheres were ready by utilizing two differentphases. One of the fluid stage ready by dissolving starch as polymer in refined water at 50°C. The necessary gauged measure of medication 5-FU accordingly added to this arrangement with nonstop mixing upto totally dissolving. Other was natural stage with oil ether, light fluid paraffin in the proportion of 50:50 w/w containing 1%w/v range 80 as surfactant. The fluid stage was then added to a natural stage, under consistent blending utilizing a mechanical stirrer to shape w/o sort of emulsion. After 10 min gluteraldehyde (1 ml) was added as cross-connecting specialist to this arrangement, the temperature of response combination was kept consistent at 40°C, with blending speed at 300 rmp

upto 4 h. The resulting microspheres were washed and filtered with n-hexane, dried under vacuum at 40°C for 12 h and stored in air tight container (Figure 11).




**Figure11: Flow diagram of method of preparation of starch Microspheres**

**Polymeric coating of starch microspheres:** The pre-arranged starch microspheres were covered with Eudragit S100 by emulsification-dissolvable vanishing technique. The created 5FU-stacked starch microspheres were moved to 10 ml of ethanolic arrangement of Eudragit S100 (10% w/v). Then, at that point, emulsification was accomplished byadding70 ml oflight paraffin and Range 80 (1%v/v)followed bystirring for 2 h at 1500 rpm with a mechanical stirrer. At long last, Eudragit S100-covered microspheres werecollected by filtration, washing with oil ether and dried in hot air stove at 50°C for 3 h.

**Table3:Composition of colon specific 5FU loaded microspheres**

| F.Code | 5FU(g) | Starch (g) | Emulsifier% (Span80) | Eudragit(%w/v) |
|---|---|---|---|---|
| FCT1 | 1 | 5 | 1 | 0 |
| FCT2 | 1 | 10 | 1 | 0 |
| FCT3 | 1 | 15 | 1 | 0 |
| FCT4 | 1 | 20 | 1 | 0 |
| FCT5 | 1 | 5 | 1 | 10 |
| FCT6 | 1 | 10 | 1 | 10 |
| FCT7 | 1 | 15 | 1 | 10 |
| FCT8 | 1 | 20 | 1 | 10 |

**Characterization of microspheres:**

**Particle size analysis:** Particle size analysis plays an important role in determining the release characteristics of drug. The sizes of microspheres were measured by using an optical microscope, andthe mean particle size was calculated by measuring nearly 200 particles with the help of a calculated ocular micrometer.

**Shape and Surface characterization by SEM:** The shape and surface attributes of the microspheres were seen by filtering electron microscopy. The freeze-dried microspheres were covered with gold utilizing a falter coater (Agar falter coater, Agar Logical, Stansted, UK) under high vacuum Microphotographs were taken on various amplification and higher amplification (500X) was utilized for surface morphology

**Figure12:Photomicrographofstarchmicrosphere(100X)**



**Figure13:SEMPhotomicrographsofstarchmicrospheres**

**Flow properties:** The flow properties of prepared microspheres were characterized for identification of flow character of powder in terms of carr's index, hausner's ratio and angle of repose. The Carr's index ((IC)) and Hausner's ratio (HR) of drug powders were calculating according to following equation: Carr's Index (IC) = ρ Tapped – ρ Bulk / ρTapped Hausner's ratio(HR)=ρ Tapped/ρ Bulk The angle of repose(θ)was measured by fixed height method. This was calculated by following equation: Angle of repose (θ) = tan-1 2 H / DWhere H is the surface area of the free standing height of the powder pile and D is diameter of pile that formed after powder flow from the glass funnel

**Percentage Yield:** The prepared microspheres with a size range of 50-150 µm were collected and weighed from different formulations. The measured weight was divided by the total amount of all non- volatile components which were used for the preparation of the microspheres.

**Table4:Flow properties of different batches of microsphere**

| Formulation code | True density (gm/cm3) | Tapped density (gm/cm3) | %Compressibility index | Angle of Repose |
|---|---|---|---|---|
| FCT1 | 0.475 | 0.231 | 8.34 | 25°.39' |
| FCT2 | 0.518 | 0.254 | 9.76 | 27°.82' |
| FCT3 | 0.537 | 0.267 | 10.46 | 29°.68' |
| FCT4 | 0.689 | 0.273 | 11.43 | 29°.18' |
| FCT5 | 0.697 | 0.337 | 13.59 | 31°.39' |
| FCT6 | 0.716 | 0.366 | 12.27 | 33°.81' |
| FCT7 | 0.853 | 0.377 | 16.55 | 35°.54' |
| FCT8 | 0.975 | 0.413 | 17.18 | 37°.72' |

**Drug Entrapment:** The different plans of the starch microspheres were oppressed for drug content. 100 mg of microspheres from all clusters were precisely gauged and squashed. The powdered of microspheres were broken up with 10ml ethanol in 100ml volumetric carafe and cosmetics the volume with pH 7.4 support. This subsequent arrangement is than separated through whatmann channel paper No. 44. After filtration, from this arrangement 10 ml was taken out and weakened up to 100 ml with pH 7.4 cushion. Again from this arrangement 2 ml was taken out and weakened up to 10 m1 with pH 7.4 support and the absorbancewas estimated at 266 nm against pH 7.4 cradle as a clear. The percentage drug entrapment was calculated as follows.

**In vitro swelling:** Not entirely settled by putting 100 mg of starch microspheres and Eudragit-covered starch microspheres as fake treatment in a cellophane film dialysis pack (D9402, Sigma-Aldrich, Mumbai), containing phosphate cushion (pH 7.4). Then, at that point, microspheres were permitted to expand for a time of 8 h. The progressions in weight were estimated by expulsion of the examples and blotched with a channel paper for 10s to retain overabundance dissolvable on surface. The level of ex Si = Wt-W0/W0where Si addresses the level of enlarging, Wt and W0 address loads of the example at harmony expanding and the first dry weight, separately.

**Table5: Characterizationof 5FU microspheres**

| Time(h) | FCT1 | FCT2 | FCT3 | FCT4 | FCT5 | FCT6 | FCT7 | FCT8 |
|---|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1.206 | 1.106 | 1.006 | 0.421 | 0 | 0 | 0 | 0 |
| 2 | 5.72 | 2.59 | 2.01 | 1.04 | 0 | 0 | 0 | 0 |
| 3 | 11.67 | 5.12 | 2.29 | 3.47 | 0.482 | 0 | 0 | 0 |
| 4 | 22.23 | 11.97 | 5.02 | 4.01 | 4.06 | 1.6 | 1.102 | 0.211 |
| 5 | 46.31 | 22.93 | 12.68 | 7.34 | 9.21 | 8.89 | 7.32 | 5.34 |
| 6 | 68.98 | 42.31 | 21.43 | 13.11 | 19.98 | 15.34 | 14.23 | 11.98 |
| 7 | 91.34 | 64.18 | 41.31 | 31.23 | 39.89 | 32.12 | 28.43 | 20.21 |
| 8 | 98.11 | 86.21 | 59.98 | 53.67 | 61.89 | 47.23 | 41.41 | 32.67 |
| 9 | 99.05 | 95.23 | 82.21 | 70.76 | 77.99 | 68.23 | 54.31 | 45.32 |




**Figure13: Zero-order plots of Colon Targeted Microsphere of 5FU(FCT1- FCT8)**




**Figure14: First-order plots of Colon Targeted Micro sphere of 5 FU (FCT**

## 5. RESULTS AND DISCUSSION

**Preformulation study:** 5-FU was gifted from Biochem Pharmaceutical Industries Ltd-Daman and identified as per tests prescribed in Pharmacopoeia of India (1996). An infrared spectrum of provided drug was found to be concordant with the reference infrared spectrum of the 5-FU. An acidic solution of 5-FU was scanned in the U.V. range of 200-400 nm using Shimadzu 1800 UV Visiblespectrophotometer as prescribed in I.P. 1996. The spectrophotometric method of analysis of 5-FU at λmax 266.0 nm was found to be reproducible and highly sensitive. The standard curves of 5-FU were prepared in simulated gastric fluid (pH 1.2) at λmax 262.0, phosphate buffer solution (pH 7.4) at λmax 266.0, simulated intestinal fluid (pH 6.8) at λmax 266.0, and simulated colonic fluid with 4% w/v rats caecal content at λmax 267.0 nm. The data were regressed to obtain The disintegration investigation of arranged uncoated and covered microsphereswas 5-FU was gifted from Biochem Drug Ventures Ltd-Daman and recognized according to tests recommended in Pharmacopeia of India (1996). An infrared range of given drug was viewed as concordant with the reference infrared range of the 5-FU. An acidic arrangement of 5-FU was checked in the U.V. scope of 200-400 nm involving Shimadzu 1800 UV Visible spectrophotometer as endorsed in I.P. 1996. The spectrophotometric strategy for examination of 5-FU at λmax 266.0 nm was viewed as reproducible and exceptionally touchy. The standard bends of 5-FU were ready in reproduced gastric liquid (pH 1.2) at λmax 262.0, phosphate cushion arrangement (pH 7.4) at λmax 266.0, reenacted

gastrointestinal liquid (pH 6.8) at λmax 266.0, and mimicked colonic liquid with 4% w/v rodents caecal substance at λmax 267.0 nm. The information were relapsed to acquire the straight line. The relationship coefficient more prominent than 0.99 was seen in every one of the cases, which showed that, the medication adheres to Brew Lambert's regulation in the fixation scope of 2-20 µg/ml. In the current review, polymers were chosen based on their solvency's and non-impedance in the assessment of medication. The absorbance information of both medication and various added substances were noted. The absorbance information had shown no obvious change in the absorbance of medication arrangement at 266.0 nm demonstrating no impedance of polymers in the assessment of 5-FU.the straight line. The correlation coefficient greater than 0.99 was observed in all the cases, which indicated that, the drug follows Beer- Lambert's law in the concentration range of 2-20 µg/ml. In the present study, polymers were selected on the basis of their solubility's and non-interference in the estimation of drug. The absorbance data of both drug and different additives were noted. The absorbance data had shown no appreciable change in the absorbance of drug solution at 266.0 nm indicating no interference of polymers in the estimation of 5- FU.

**Characterization of microspheres:**

The particle size was calculated by measuring nearly 200 particles with the help of a calculated ocular micrometer. The shape and surface characteristics of the microspheres were observed by scanning electron microscopy. Microphotographs were taken on different magnification and higher magnification (500X) was used for surface morphology. The microspheres were shown rough surface structure and observe ballon like structure shown inFigure12–13. The stream properties of arranged microspheres were portrayed for ID of stream character of powder with regards to carr's record, hausner's proportion and point of rest. Stream properties of various groups of microsphere were shown in Table4 and werehave great to fair flow in characterstics in light of the fact that of rough surface structure of prepared microspheres. The result ofmeanparticlesize36.99 - 121.72µm, rate yield of various bunches of microsphere have differed from 92.86 ± 0.14 % - 92.86 ± 0.14 %. The rate drug capture was determined of various bunches of microsphere were showed more medication stacking limit with respect to covered microspheres differed from 95.21 ± 0.24 % - 100.09 ± 0.97 %. In vitro swellingwas decided byallowingswellingforaperiodof8 h. Thechanges in weight weremeasured and level of enlarging of various groups of microsphere was relying upon the higher level of starch polymer during the plan and was fluctuated from 14.14 ± 0.36 - 35.23 ± 0.42 in Table 5. The in-vitro drug discharge investigations of uncoated and covered microspheres was led in a USP paddle device in various pH condition for 5FU. The outcomes were displayed in Figure 4.11 - 4.14 and Table 6. The in-vitro Delivery profile of microspheres was described for discharge rate and delivery rate k. Discharge information inside the direct reach were chosen and fitted to a zero-request numerical model:

$$Q = C + kt$$

Where Q is the delivery rate at time t; k is the incline of the fitted straight condition and hererepresents discharge rate; and C is the block of the direct condition. Tlag is characterized as the hour of the beginning of plumbagin discharge and determined here from the fitted condition, setting Q=0:

Tlag=-C/k.

CTmicrospheresFCT6isthebestformulationscontainingnaturallyoccurringpolysaccharidepolymeric mix as for example starch with 10 % eudragit S100 covering that discharge more than 99 % of the medication in gastric climate in controlled and supported way upto 12 h.Relapse examination was performed and the r2 values recommended that the bends were genuinely straight and slant values were processed from the chart. The delivery type "n" values were in the scope of 1.1212 to 1.3219 for FCT1 to FCT8 (Table 7).For all of the batches the value of release exponent “n” was > 0.89 indicating Super-case II transport mechanism.

## 6. CONCLUSION:

5FU medication was assessed in-vitro by detailed UV spectrophotometric techniques in the various dissolution medium i.e.0.1 NHCl solution, phosphate buffer H7.4 and phosphate buffer H6.8 arranged with drug arrangements of known focuses. 5-FU was concentrated by dissolvability concentrate on in various solvents at room temperature uncovered that it is dissolvable in refined water and insoluble in chloroform, benzene and so on. Segment coefficient worth of 5-FU additionally uncovered its hydrophilic nature The spectrophotometric strategy for examination of 5-profoundly delicate. The standard bends of 5-FU were ready in recreated gastric liquid (pH 1.2) at λmax 262.0, phosphate support arrangement (pH 7.4) at λmax 266.0, reproduced digestive liquid (pH 6.8) at λmax 266.0, and reenacted colonic liquid with4% w/v rodents caecal substance at λmax 267.0nm.The molecule size, theshapeandsurfacecharacteristicsofthemicrospheres,flowproperties, rate yield,drugloading limit and level of enlarging of various clumps of microsphere was examined and the outcome was presumed that these were relying upon the higher level of starch polymer during the detailing. The in-vitro drug discharge investigations of uncoated and covered microspheres was led in a USP paddle device in various pH condition for 5FU. CT microspheres FCT6 is the best details containing normally happening polysaccharide polymeric mix as for example starch with 10 % eudragit S100 covering that releasemorethan 99 %ofthedrugin gastricenvironment in controlled and sustainedmanner upto 12 h. Relapse examination was performed and the r2 values proposed that the bends were genuinely direct and slant values were registered from the chart. The delivery example "n" values were in the scope of 1.1212 to 1.3219 for FCT1 to FCT8.For every one of the bunches the worth of delivery type "n" was > 0.89 demonstrating Super-case II vehicle component.

**REFERENCES**

1. Albanes D., Malila N., Taylor P.R., (2000) Effects of supplemental a-tocopherol and ß-carotene on colorectal cancer: results from a controlled trial (Finland), Cancer Causes Control. 11(3), 197-205.

2. Alimi D., Rubino C., Leandri E.P. Brule S.F., (2000) Analgesic effects of auricular acupuncture for cancer pain, J P Symp Man.19(2), 81-82.

3. Annamalai M., Shabana S., Klimkowsky D., Nyamweya N., (2005) Compression of EUDRAGIT® FS 30D coated Theophylline granules with different microcrystalline cellulose grades. S.T.P. Pharma Sci. 6(3), 217- 218.
4. Asghar Ali, Fatima Laila and Chandran Sajeev., (2006)Multiparticulate Formulation Approach to Colon Specific Drug Delivery: Current Perspectives J Pharm Pharmaceut Sci (www.cspscanada.org) 9(3):327-338,
5. Ashford M, Fell T., (1994) Targeting drugs to colon: delivery system for oral administration. J Drug Target 2:241Y258
6. Carethers, (2008)Aspirin Dose and Duration of Use and Risk of Colorectal Cancer in Men. Gastroenterology Volume 134, Issue 1, Pages 21-28, January
7. ChaurasiaM.,ChaurasiaM.K.,JainN.K.,Soni V.,GuptaY.,JainS.K.,(2006)Cross linkedguargum microspheres:aviableapproach forimproveddeliveryofanticancer drug for the treatment of colorectal cancer, AAPS Pharma Sci Tech.7(3) 74-74
8. Chaurasia M.K, and Jain S.K., (2003) Pharmaceutical approaches to colon targeted drug delivery system, J Pharm Sci.6(1), 33-66.
9. DawangSR,SabooSS, KhadabadiS, "Formulation and evaluation of floating tablets of Verapamil hydrochloride by using gastroretentive technology." Int. J. Pharm. Sci. Rev. Res. 2015, 34, 1, 263-269.
10. Dey N.S., Majumder S.and Rao M., (2008) "Multiparticulate drug delivery systems forcontrolled Release", Trop Jour of Pharm Res. September7 (3)1068-1068.
11. DhawaleS.C.,BankarA.S.,PatroM.N.,(2010)formulationandEvaluationPorous Microspheres of 5- Fluorouracil for Colon Targeting, International Journal of PharmTech Research CODEN(USA):IJPRIFISSN:0974-4304Vol.2,No.2,pp 1112-1118,April-June
12. El Nabarawi MA, Teaima MH, El-Monem RA, El Nabarawy NA, Gaber DA. "Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl.".
13. Florey, K., In: (1973) analytical Profil Drug Substance, Academic Press, New York, 2, 221-240.
14. Giovannucci E., (2004) Alcohol, one-carbon metabolism, and colorectal cancer: recent insights from molecular studies, J Nutr.134, 2475-2481.
15. Hou J, Yuntai S, Zihao L, Jiaqi W, Yongjun G, Weifeng Z, Han Z, Dayong N, "Numerical simulation and experimental study on flexible buoyancy material of hollow glass microsphere and silicone rubber for small deep-sea soft robots." App. Mat. Today.2020, 21, 100875.
16. Ibekwe V. C., Khela M. K., Evans D. F., Basit A. W., (2008) A new concept in colonic drug targeting: a combined pH-responsive and bacterially-triggered drug delivery technology. Alimentary Pharmacology & Therapeutics, 28(7), 911–916,
17. Jafar M, Mohsin AA, Khalid MS, Alshahrani AM, Alkhateeb FS, Alqarni AS, "Ranitidine hydrochloride stomach specific bouyant microsponge: Preparation, in- vitro characterization, and in-vivo anti-ulcer activity." J. Drug Del. Sci. Tech. 2020, 55, 101453,
18. Jain A.,Gupta Y., Jain S.K., (2007) Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon, J Pharmaceut Sci. 10(1), 86-128.
19. Jain M N, "Development and characterization of gastro retentive muco adhesive tablets of riboflavin." Ind. J. Drug. 2018, 6, 2, 105-111.
20. Jain,N.K.,(2002)AdvancesinControlandNovelDrugDelivery,CBSPublisherNewDehli,201-205.
21. Khosla, R., Davis, S.S., (1987) The effect of polycarbophil on the gastric emptyingof pellets. J. Pharm. Pharmacol., 39, 47–49
22. KrishnaiahY.S.R.,SatyanarayanS.,(2001)Colon-specificdrugdeliverysystems,In: Jain NK, ed. Advances in Controlled and Novel Drug Delivery New Delhi, India: CBS Publishers and Distributors; 89, 119.
23. Kumari SU, Ramu B, Srikanth G, Rajkamal B, "Formulation and Evaluation of Sustained Release Verapamil Hydrochloride Using Natural Polymers."Int. J. App. Pharm. Sci. Res. 2016, 1, 2, 76-87.
24. Lecomte Florence, Siepmann Juergen, Mathias Ross J. MacRae, and Roland (2005) pH-Sensitive Polymer Blends used as Coating Materials to Control Drug Release from Spherical Beads:Importance of the Type of Core. Biomacromolecules 6(4), 2074–2083.
25. Lueben H.L., Lehr, C.-M., Rentel, C.-O., Noach, A.B., de Boer, J.A.G., Verhoef, J.C., Junginger, H.E., (1994) Bioadhesive polymers for the peroral delivery of peptide drugs. J. Control. Release, 29, 329–338.